Changdu Bio · CD BIOENG. & THERAPY

Printing Health for Life: Bioprinted Tumor Organoid Drug Sensitivity Testing

Using a patient's own tumor cells to print three-dimensional organoid models, testing drugs outside the patient's body on their behalf. Engineered precision control with controllable structure turns "preoperative in vitro stand-in drug testing" from research papers into a routine clinical service.

Core Metrics

Four Sets of Numbers Already Proven

Modeling success rate

98% (engineered precision control, stable model culture)

Report delivery

As fast as 8 days

Clinical test cases

Over 3,000 individualized drug sensitivity tests completed, covering multiple tertiary hospitals nationwide

Partner medical institutions

100+ tertiary hospitals (Beijing 23, Shanghai 21, Guangdong 27, Henan 30, Zhejiang 26, Sichuan 16, etc.)

Technical Approach

Bioprinted Organoids vs. Traditional Organoids

Analogy

A designed and planted garden — engineered precision control, controllable structure; the traditional approach is closer to "natural growth," with consistency left to chance

Modeling success rate

Bioprinting approach about 98%, stable and reproducible model culture

Turnaround

After process standardization, reports in as fast as 8 days, keeping pace with clinical decision-making

Structural controllability

Printing paths, cell distribution, and matrix structure are program-controlled, with minimal batch-to-batch variation

Application scenarios

Preoperative medication plan reference, parallel in vitro comparison of multiple plans, drug resistance and sensitivity assessment

Laboratories

National Medical Laboratory Layout

City	Location	Scale	Status
Beijing	Dongcheng District core urban area	Approx. 1,200 sqm	Completed
Shanghai	Fenglin Life Health Industrial Park, Xuhui District (adjacent to Fudan Cancer Center and Zhongshan Hospital)	Approx. 1,300 sqm	Completed
Ningbo	Xiaogang, Beilun District (Phase II located in Haier Shi's industrial park under construction)	Phase I nearly 1,000 sqm, Phase II approx. 2,000 sqm	Completed
Chengdu	West China Health Valley (industrial park in deep cooperation with West China Hospital)	Approx. 1,200 sqm	Under construction
Zhengzhou	Central urban commercial area, adjacent to the First Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, and Henan Cancer Hospital	Approx. 1,500 sqm	Under construction
Guangzhou	Liuhua Center (former Canton Fair site, reaching ASEAN countries)	Approx. 2,500 sqm	Site selection in progress

Team

Who Is Behind This

Company background

Jointly founded by a professor team from Peking Union Medical College Hospital, a professor team from Tsinghua University, and Haier Shi Biopharmaceutical Co., Ltd.

Team size

100+ people, including 12 PhDs

Academic output

44 authoritative papers, including Gut, Molecular Cancer, Science Advances, Advanced Science, Biomaterials, etc.

Intellectual property

20+ applications

Academic society positions

The Biomedical 3D Printing Branch of the Chinese Society of Biomedical Engineering was established; Professor Sun Wei of Tsinghua University serves as the first chairman; Yu Jianwei, Chairman of Haier Shi Group, serves as vice chairman; Xie Zhibo, Medical Director of Changdu Bio, was elected as a committee member

Scientific advisors

Yang Huayu (Researcher, Department of Liver Surgery, Peking Union Medical College Hospital), Mao Yilei (Professor of Liver Surgery, PUMCH; Founding Editor-in-Chief of HBSN), Pang Yuan (Associate Researcher, Tsinghua University), Sun Wei (Professor, Tsinghua University; Founder of SunP Biotech)

Qualifications

Standards and Projects

2026 Smart Healthcare Insurance Competition

First prize, ranked 1st among 240 finalists — recognised by China's National Healthcare Security Administration

Group standard

Led the formulation of "General Requirements for 3D Bioprinted Tumor Models" — the first group standard in this field domestically and internationally

Quality control

Established SOP for drug sensitivity testing workflow; published "Quality Control Standards for 3D Bioprinted Tumor Model Diagnosis and Treatment Platform"

National-level project

Approved for the 2024 National Key R&D Program project: Additive Manufacturing of Fine Multicellular Microenvironment Organ Chips and Clinical Drug Screening

Development history

2016 initiated bioprinting exploration → 2018–2020 expanded to clinical trials for individualized medication guidance in liver cancer, cholangiocarcinoma, colorectal cancer, pancreatic cancer, ovarian cancer, glioma, and other cancer types → platform continues to expand to date

Research Directions

Where the Platform Is Extending

Tumor immune microenvironment

Drug screening models

Metabolism and endocrinology

Human islet tissue models, liver metabolic rare disease models, NAFLD models, NASH models

Neurodegeneration

In vitro Alzheimer's disease models

Ophthalmology

Keratoconus models, retinal macular degeneration models

Dermatology

Skin bullous disease models

CD BIOENG. bio-3D printed tumour organoid drug-sensitivity testing poster — CD BIOENG. — commemorating the founding of the Bio-3D Printing Branch, Chinese Society of Biomedical Engineering

FAQ

Four Questions Most Asked by Clinical and Research Partners

What clinical problem does this test solve?

Before a patient officially starts medication, their own tumor cells are used to construct organoid models in vitro and test multiple drug regimens, providing reference for clinical selection — what is called "preoperative in vitro stand-in drug testing."

What sample is needed? How long for results?

Typically tumor tissue obtained from surgery or biopsy. After process standardization, reports can be issued in as fast as 8 days; actual turnaround depends on sample conditions and test items. Please confirm with the laboratory before sending samples.

How is this different from traditional organoid methods?

The traditional approach is closer to natural growth with greater batch variation; bioprinting program-controls printing paths, cell distribution, and matrix structure, achieving controllable and reproducible structures with a modeling success rate of about 98%.

Can we collaborate on research projects?

Yes. The company has long-term joint research with teams from PUMCH, Tsinghua, and other institutions, and also undertakes model construction and drug screening collaborations with hospitals and pharmaceutical companies. Please contact us directly for specific directions and scheduling.

For clinical collaboration, sample submission, and research projects, contact us directly

Wu Huiyou　+86 130 7553 2468　(WeChat same number, scan code to add)

Call for Consultation→

Contact

Clinical collaboration / sample submission / research projects

武慧友

CD BIOENG. & THERAPY CO., LTD.

+86 130 7553 2468

Same number on WeChat. Call directly, or scan the code to add us.